MRI (magnetic resonance imaging) agent OptiMARK approved:
This article was originally published in Clinica
Executive Summary
Mallinckrodt's MRI contrast agent for brain, spine and liver imaging, OptiMARK, has been cleared for sale in the US. The St Louis, Missouri-based company said the agent, which will be on sale in the first quarter of 2000, will be in a $150 million market experiencing 12%-15% growth per year.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.